Contraindications: Tren Ace 150 is contraindicated in individuals with known hypersensitivity to trenbolone or any oil-based injectable excipient, existing hepatic impairment, active cardiovascular disease including left ventricular hypertrophy, prostate or breast carcinoma, and all individuals under 21 years of age. Females should not use this compound due to irreversible virilisation risk.
Side Effects: Androgenic effects including acne, accelerated scalp hair thinning, and increased sebum production are concentration-dependent. Cardiovascular effects — notably elevated haematocrit, reduced HDL cholesterol, and increased blood pressure — require active monitoring throughout any Trenbolone Acetate protocol. Neurological effects such as heightened aggression and altered mood patterns are reported and should be tracked daily when using microdosing schedules. Tren cough (a transient acute bronchospasm-like response) may occur immediately post-injection regardless of dose size.
Monitoring: Blood panels including full lipid profile, haematocrit, haemoglobin, liver enzyme markers (ALT/AST), and blood pressure readings should be obtained at baseline, at the midpoint of any cycle, and within two weeks of cycle completion. Daily microdosing does not eliminate the need for periodic monitoring — it makes mid-cycle bloodwork more actionable because dose adjustments propagate quickly through the short ester's clearance window.
PCT: Post-cycle therapy is mandatory following all Trenbolone Acetate protocols regardless of dose magnitude. A selective oestrogen receptor modulator (SERM) — typically Clomiphene or Tamoxifen — should be initiated no earlier than 3 days after the final injection, allowing the acetate ester to clear sufficiently. Duration of PCT is typically 4 weeks, adjusted according to cycle length and total weekly androgen load used.